N. Girard

The IASLC Lung Cancer Staging Project: Analysis of Resection Margin Status and Proposals for Residual Tumor Descriptors for Non–Small Cell Lung Cancer

John Edwards, Kari Chansky, Paul Van Schil et al. · Journal of Thoracic Oncology · 2019 · 157 citations · Full text

Medicine, Oncology, Surgery +16

Abstract CT003: Nivolumab (NIVO) + platinum-doublet chemotherapy (chemo) vs chemo as neoadjuvant treatment (tx) for resectable (IB-IIIA) non-small cell lung cancer (NSCLC) in the phase 3 CheckMate 816 trial

Patrick M. Forde, Jonathan Spicer, Shun Lü et al. · Cancer Research · 2021 · 99 citations

Medicine, Oncology, Pharmacology +15

Amivantamab plus lazertinib versus osimertinib in first-line EGFR-mutant advanced non-small-cell lung cancer with biomarkers of high-risk disease: a secondary analysis from MARIPOSA

Enriqueta Felip, Byoung Chul Cho, Adlinda Alip et al. · Annals of Oncology · 2024 · 81 citations · Full text

Medicine, Oncology, Pharmacology +17

IFCT-1502 CLINIVO: Real-life experience with nivolumab in 600 patients (pts) with advanced non-small cell lung cancer (NSCLC): Efficacy and safety of nivolumab and post-nivolumab treatment in the French Expanded Access Program (EAP)

N. Girard, Clarisse Audigier-Valette, Jacques Cadranel et al. · Annals of Oncology · 2017 · 12 citations · Full text

Medicine, Oncology, Pharmacotherapy +10

LBA54 Amivantamab plus chemotherapy vs chemotherapy in EGFR-mutated, advanced non-small cell lung cancer after disease progression on osimertinib: Second interim overall survival from MARIPOSA-2

S. Popat, K.L. Reckamp, Raffaele Califano et al. · Annals of Oncology · 2024 · 12 citations · Full text

Medicine, Oncology, Pharmacology +16